Aiming to validate SMC2 as a CSC target, SMC2 was silenced in different cancer cell lines (HT116, MDA-MB-231 and PANC-1, from colorectal, breast and pancreatic origin) using RNA interference technology. The gene discussed is SMC2; the disease is cancer.